Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 2012

View Archived Issues

Shire provides pipeline overview for third quarter of 2012

Lupin presents novel nicotinic acetylcholine receptor modulators

Neuraltus Pharmaceuticals reports phase II results for NP-001 in ALS

Ocular Therapeutix reports results from phase II OTX-TP2 study

Ultragenyx completes enrollment in phase II UX-001 study

Kyowa Hakko Kirin reviews developments of third quarter 2012

Adcetris granted conditional approval in Europe for two indications

Summit initiates phase I study of SMT-19969 for C. difficile infection

RaQualia Pharma and Ajinomoto Pharmaceuticals establish collaboration

Results from phase III study of masitinib plus Gemzar for pancreatic cancer presented

Shionogi and Janssen enter collaboration for Alzheimer's disease

Two Cytori cell therapy studies approved by Japanese authorities

Key milestone reached for TSRL with the FDA for TSR-026

Roche presents new SYK kinase inhibitors

Korean scientists patent novel DPP IV inhibitors

Incyte discloses new PI3Kdelta inhibitors

New nACh alpha7 receptor modulators patented by Lundbeck

Novel cannabinoid CB1 receptor antagonists synthesized by Korean group

Results presented for randomized phase II study of tivantinib

Bristol-Myers Squibb divulges new prodrugs of LXR modulators

Results presented from phase II trial of dovitinib in GIST

Strategic collaboration reached for Firdapse in North America

Phenex's PX-102 proves safe and well tolerated in phase I study

Novo Nordisk completes phase I trial of oral GLP-1 analogue

Avastin obtains E.U. approval for recurrent, platinum-sensitive ovarian cancer

Karo Bio presents agent with potential for preventing multiple sclerosis progression

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...